Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
OBJECTIVE
Prior to the Food and Drug Administration approval of 4-factor prothrombin complex concentrate (4F-PCC), only 3-factor PCC (3F-PCC) products were available in the US. There is limited data comparing the safety and efficacy of 3F-PCC versus 4F-PCC. The purpose of our study, therefore, was to compare the safety and efficacy profiles of 3F-PCC versus 4F-PCC for the emergent reversal of warfarin.


METHODS
A single-center, retrospective cohort analysis compared patients who received 3F-PCC or 4F-PCC for the emergent reversal of warfarin due to life-threating bleeding from January 2013 to September 2015. The primary objective of this study was the percentage of patients whose international normalized ratio (INR) reversed to ≤1.5 within 8h of PCC administration. The secondary safety objective was incidence of thromboembolic events at 7days post PCC.


RESULTS
A total of 137 patients were included. The median baseline INR was 3.15 in the 3F-PCC group and 3.1 in the 4F-PCC group. The median post-PCC INR was 1.4 in the 3F-PCC group and 1.3 in the 4F-PCC group. INR ≤1.5 was achieved in 45/58 (78%) patients in the 3F-PCC group and 46/58 (79%) patients in the 4F-PCC group (p=0.61). The thromboembolic event rate between the two groups at 7days was similar, 4/68 (5.9%) for 3F-PCC versus 4/69 (5.8%) for 4F-PCC (p=1.0).


CONCLUSIONS
There was no significant difference in the percentage of patients who achieved an INR ≤1.5 between the 3F-PCC and 4F-PCC groups for emergent reversal of warfarin.
Department of Pharmacy, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212, United States. Electronic address: jkuroski59@gmail.com.
Julia E
JE
Kuroski
Department of Pharmacy, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212, United States. Electronic address: sarah.young@ahn.org.
Sarah
S
Young
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D019934:International Normalized Ratio; D008297:Male; D061214:Patient Safety; D012189:Retrospective Studies; D062606:Tertiary Care Centers; D013923:Thromboembolism / Q000188:drug therapy*; D014481:United States; D014859:Warfarin / Q000009:adverse effects*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D014859:Warfarin
Anticoagulation reversal; Prothrombin complex concentrate; Thromboembolic events; Warfarin